Urovant Sciences Ltd.
(NASDAQ GS: UROV)
Rigrodsky Law, P.A. is investigating Urovant Sciences Ltd. (“Urovant”) regarding possible breaches of fiduciary duties and other violations of law related to Urovant's agreement to be acquired by Sumitovant Biopharma Ltd. Under the terms of the agreement, Urovant's shareholders will receive $16.25 in cash per share.